Skip to content
10-K

Annual Report

Sagimet Biosciences Inc. SGMT

0001104659-26-026140

← back to feed
Filed
Mar 11, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2025 · Dec 31, 2025 32.35M sh
Shares Diluted FY 2025 · Dec 31, 2024 31.35M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$45.65M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$42.44M
Cash And Equivalents FY 2025 · Dec 31, 2025 $35.02M
Cash And Equivalents FY 2025 · Dec 31, 2024 $75.84M
Stockholders Equity FY 2025 · Dec 31, 2025 $111.38M
Stockholders Equity FY 2025 · Dec 31, 2024 $155.81M
Stockholders Equity FY 2025 · Dec 31, 2023 $91.07M
Current Liabilities FY 2025 · Dec 31, 2025 $5.1M
Current Liabilities FY 2025 · Dec 31, 2024 $4.45M
Current Assets FY 2025 · Dec 31, 2025 $116.4M
Current Assets FY 2025 · Dec 31, 2024 $152.77M
Total Assets FY 2025 · Dec 31, 2025 $116.48M
Total Assets FY 2025 · Dec 31, 2024 $160.26M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.58
Eps Diluted FY 2025 · Dec 31, 2024 −$1.45
Eps Basic FY 2025 · Dec 31, 2025 −$1.58
Eps Basic FY 2025 · Dec 31, 2024 −$1.45
Sga Expense FY 2025 · Dec 31, 2025 $17.84M
Sga Expense FY 2025 · Dec 31, 2024 $16.01M
Rd Expense FY 2025 · Dec 31, 2025 $39.05M
Rd Expense FY 2025 · Dec 31, 2024 $38.44M
Net Income FY 2025 · Dec 31, 2025 −$51.04M
Net Income FY 2025 · Dec 31, 2024 −$45.57M
Operating Income FY 2025 · Dec 31, 2025 −$56.89M
Operating Income FY 2025 · Dec 31, 2024 −$54.45M